Reaction
Osteosarcoma reporting signals
As of the last recalculation, Osteosarcoma appears in 380 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 166.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 27 | 166.6 | 167.1 |
| Ifosfamide | 51 | 150.0 | 150.4 |
| Etoposide | 73 | 67.1 | 67.1 |
| Melphalan | 25 | 64.4 | 64.4 |
| Melphalan Hydrochloride | 26 | 60.9 | 61.0 |
| Cisplatin | 67 | 56.8 | 56.9 |
| Bleomycin Sulfate | 9 | 48.9 | 48.9 |
| Mesna Injection | 6 | 40.4 | 40.4 |
| Mesna | 6 | 39.6 | 39.7 |
| Doxorubicin | 55 | 39.4 | 39.4 |
| Regorafenib | 8 | 38.5 | 38.6 |
| Pazopanib Hydrochloride | 17 | 36.0 | 36.0 |
| Sorafenib | 12 | 32.6 | 32.7 |
| Somatropin | 16 | 12.4 | 12.4 |